Word: fosamax
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...shown to reduce the risk of fractures in postmenopausal women as well as men being treated for prostate cancer, the two largest patient populations at risk for bone loss. What's not clear, however, is how the new drug, if approved, would compare with existing osteoporosis drugs like Fosamax, Boniva and Reclast...
...existing bone, the new data suggest that denosumab may be more effective in promoting bone density. In addition, the studies show that denosumab did not cause the serious side effects - including cancer and the disintegration of bone in the jaw - that are associated with bisphosphonate drugs like Boniva, Fosamax and Reclast, the most commonly prescribed osteoporosis drugs on the market. (See TIME's special report "America...
...clear how denosumab, should it win approval, would fit into the anti-osteoporosis market for treating postmenopausal women. Among these patients, the study suggests, the experimental compound would be slightly more effective at reducing fractures than the bisphosphonate drugs Fosamax (alendronate) and Boniva (ibandronate), but no better than Reclast (zoledronic acid), the once-a-year solution that doctors administer intravenously...
...looking for a solution to osteoporosis at the pharmacy, be cautious. Many women cannot tolerate the side effects of the popular bisphosphonate drugs: Fosamax, Actonel and Boniva. The most common problem is gastroesophageal irritation, but dentists and oral surgeons have begun to warn of a more serious problem in a subgroup of patients--necrosis (death) of the jawbone...
...enough for Merck shareholders that the firm's top drugs, Zocor and Fosamax, are going off patent over the next three years and that the pipeline looks thin. Now investors may have to stomach another bitter pill. A Texas jury last week awarded $253.5 million to the widow of a man who died after taking the painkiller Vioxx. In the first verdict reached in more than 4,000 liability cases involving the drug--which Merck recalled last year after studies indicated a possible link to heart failure--the award cast doubt on Merck's strategy of fighting each case individually...